BioCorRx Inc (BICX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BioCorRx Inc (BICX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9443
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioCorRx Inc (BioCorRx), formerly Fresh Start Private Management Inc, is a healthcare solution provider. The company provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers. It distributes and licenses BioCorRx recovery program, a medication-assisted treatment (MAT) program that includes a counseling program coupled with its proprietary naltrexone implant. It also develops BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. BioCorRx is headquartered in Anaheim, California, the US.

BioCorRx Inc (BICX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioCorRx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioCorRx Inc, Medical Devices Deals, 2012 to YTD 2018 10
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
BioCorRx Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Biocorrx Acquires Portfolio from Therakine Biodelivery 12
BioCorRx Acquires Intellectual Property and Contractual Rights of Well Advised 13
Private Equity 14
Alpine Creek Capital Partners to Invest USD1.66 Million in BioCorRx 14
Partnerships 15
BioCorRx Enters into Licensing Agreement with Therakine 15
BioCorRx to Enter into Agreement with VDM Biochemicals 16
Licensing Agreements 17
BioCorRx Enters into Licensing Agreement with Fresh Start Private Midwest 17
Equity Offering 18
BioCorRx Raises USD1.1 Million in Private Placement of Units 18
Debt Offering 19
BioCorRx Raises USD0.08 Million in Private Placement of Note 19
BioCorRx Raises USD0.08 Million in Private Placement of Note 20
BioCorRx Raises USD0.3 Million in Private Placement of Note 21
BioCorRx Inc – Key Competitors 22
BioCorRx Inc – Key Employees 23
BioCorRx Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Product News 25
07/25/2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio 25
07/06/2017: BioCorRx to Exhibit at ASAM Conference in Dallas, Texas 26
05/22/2018: BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102 27
04/30/2018: BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant 28
04/26/2018: BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company’s Sustained Release Naltrexone Implant for Alcohol Use Disorder 29
04/05/2018: BioCorRx Partner, Virtual Reality Medical Center, Submits Small Business Innovation Grant Application to the National Institute of Health 30
01/05/2018: BioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone 31
01/02/2018: BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic 32
Product Approvals 33
Feb 12, 2018: BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102 33
Dec 19, 2017: BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102 34
Sep 28, 2017: BioCorRx Announces Update on Commercialization Efforts for Naltrexone Implant 35
Jan 12, 2017: BioCorRx Retains Innovative Science Solutions to Guide FDA Regulatory Process for its Naltrexone Products 36
Other Significant Developments 37
Apr 06, 2018: BioCorRx Provides Business Update for the Full Year Ended 2017 37
Mar 15, 2018: BioCorRx Provides Update on New Weight Management Program 39
Nov 17, 2017: BioCorRx Provides Business Update for the Third Quarter of 2017 40
Sep 12, 2017: BioCorRx Announces Beta Launch of Mobile Application for Opioid and Alcohol Substance Use Disorder 41
Aug 15, 2017: BioCorRx Reports 12% Increase in Revenue and Provides Business Update for the Second Quarter of 2017 42
Jul 31, 2017: Serrano Kidney and Vascular Access Center to Implement the BioCorRx Recovery Program for the Hispanic Market in Los Angeles 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
BioCorRx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioCorRx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioCorRx Inc, Deals By Therapy Area, 2012 to YTD 2018 9
BioCorRx Inc, Medical Devices Deals, 2012 to YTD 2018 10
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Biocorrx Acquires Portfolio from Therakine Biodelivery 12
BioCorRx Acquires Intellectual Property and Contractual Rights of Well Advised 13
Alpine Creek Capital Partners to Invest USD1.66 Million in BioCorRx 14
BioCorRx Enters into Licensing Agreement with Therakine 15
BioCorRx to Enter into Agreement with VDM Biochemicals 16
BioCorRx Enters into Licensing Agreement with Fresh Start Private Midwest 17
BioCorRx Raises USD1.1 Million in Private Placement of Units 18
BioCorRx Raises USD0.08 Million in Private Placement of Note 19
BioCorRx Raises USD0.08 Million in Private Placement of Note 20
BioCorRx Raises USD0.3 Million in Private Placement of Note 21
BioCorRx Inc, Key Competitors 22
BioCorRx Inc, Key Employees 23

List of Figures
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioCorRx Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[BioCorRx Inc (BICX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Daniel Thwaites Plc:企業の戦略・SWOT・財務分析
    Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report Summary Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Sharp Corp (6753):企業の財務・戦略的SWOT分析
    Sharp Corp (6753) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bionik Laboratories Corp (BNKL):医療機器:M&Aディール及び事業提携情報
    Summary Bionik Laboratories Corp (Bionik) is a medical device company that designs and develops transformational technologies, prosthetics and assisted robotic products and solutions. The company provides rehabilitation technology that senses patient movements and limitations. It provides lower body …
  • Luminex Corp (LMNX)-医療機器分野:企業M&A・提携分析
    Summary Luminex Corp (Luminex) is a medical devices company which develops, manufactures and markets proprietary biological testing technologies. The company offers wide range of products including instruments, assays, reagents and accessories, software and replacement parts. Its proprietary technol …
  • Concardis Gmbh:企業の戦略・SWOT・財務分析
    Concardis Gmbh - Strategy, SWOT and Corporate Finance Report Summary Concardis Gmbh - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Canadian Broadcasting Corp:企業の戦略的SWOT分析
    Canadian Broadcasting Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Take-Two Interactive Software, Inc.:企業の戦略・SWOT・財務情報
    Take-Two Interactive Software, Inc. - Strategy, SWOT and Corporate Finance Report Summary Take-Two Interactive Software, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Quaker Chemical Corp (KWR):企業の財務・戦略的SWOT分析
    Quaker Chemical Corp (KWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nagacorp Ltd:企業の戦略・SWOT・財務情報
    Nagacorp Ltd - Strategy, SWOT and Corporate Finance Report Summary Nagacorp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • GC Pharma (006280):企業の財務・戦略的SWOT分析
    GC Pharma (006280) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Syngen Biotech Co Ltd (8279)-製薬・医療分野:企業M&A・提携分析
    Summary Syngen Biotech Co Ltd (Syngen), a part of Standard Chem& Pharm Co Ltd, is a biotechnology company that specializes in strain identification, micro-organism fermentation, recovery, and purification. The company research, develops, manufactures and distributes active pharmaceutical ingredients …
  • Lockheed Martin Aeronautics Company:企業の戦略・SWOT・財務情報
    Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Neuralstem Inc:企業のM&A・事業提携・投資動向
    Neuralstem Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Neuralstem Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • BAE Systems Australia:企業の戦略・SWOT・財務情報
    BAE Systems Australia - Strategy, SWOT and Corporate Finance Report Summary BAE Systems Australia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Transgene Biotek Ltd (526139):企業の財務・戦略的SWOT分析
    Summary Transgene Biotek Ltd (Transgene) is a biotechnology company that develops and commercializes bio-generic drugs and vaccines to treat autoimmune diseases and cancer. The company’s product portfolio includes TrabiDHA, a vegetarian source of DHA (Docosahexaenoic acid), used to manufacture healt …
  • Radico Khaitan Ltd.:企業の戦略・SWOT・財務分析
    Radico Khaitan Ltd. - Strategy, SWOT and Corporate Finance Report Summary Radico Khaitan Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Zenkyoren:企業の戦略・SWOT・財務情報
    Zenkyoren - Strategy, SWOT and Corporate Finance Report Summary Zenkyoren - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • KPC Pharmaceuticals Inc (600422):製薬・医療:M&Aディール及び事業提携情報
    Summary KPC Pharmaceuticals Inc (KPC), formerly Kunming Pharmaceutical Corp, a subsidiary of Holley Group Co Ltd, is a manufacturer of botanical drugs and other pharmaceutical products. The company offers panax notoginseng, gastrodine, artemether and special botanical drugs. It also offers drugs suc …
  • McCarthy Building Companies Inc:企業の戦略的SWOT分析
    McCarthy Building Companies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Mayo Clinic:医療機器:M&Aディール及び事業提携情報
    Summary Mayo Clinic (Mayo) is a not-for-profit medical practice and medical research organization. It provides comprehensive medical facilities and programs related to patient care services, research and medical education. It offers specialized medical care with medical departments and centers in mo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆